Vildagliptin delayed

November 7, 2007 at 2:57 pm | In Prescribing Extra - Drugs | Print Print | 1 Comment

The launched of vildagliptin (Glavus®) has been delayed by a safety update on liver enzyme elevations according to PharmaTimes.

The article states that liver enzyme elevations were less frequent in patients taking 50mg each day or 50mg twice daily compared to those taking 100mg daily. This finding has raised safety concerns and may impact on the use of this drug as a true once-daily medication.

Action: The gliptins are new agents and their place in therapy is where other agents have failed or are not tolerated. Previous recommendations are unchanged.

Copyright ©2007 Prescribing Advice for GPs

1 Comment »

RSS feed for comments on this post. TrackBack URI

  1. [...] This provides some reassurance with respect to the liver enzyme elevations that delayed the drugs launch however patients with clinically significant liver disease or abnormal liver enzyme results at [...]

    Pingback by Prescribing Advice for GPs » Longer term gliptin data — May 22, 2009 #

Leave a comment

XHTML: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS Feed for New Entries.
Akismet has protected Prescribing Advice for GPs from 5,902 spam comments.